Oral Contraceptives (Birth Control Pills) and Cancer Risk (2024)

  • Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. American Journal of Obstetrics and Gynecology 2004; 190(4 Suppl):S5–22.

    [PubMed Abstract]
  • Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: Relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Annals of Epidemiology 2015; 25(3):193–200.

    [PubMed Abstract]
  • Wentzensen N, Berrington de Gonzalez A. The Pill's gestation: From birth control to cancer prevention. Lancet Oncology 2015; 16(9):1004–1006. doi: 10.1016/S1470-2045(15)00211-9

  • Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017):1713–1727.

    [PubMed Abstract]
  • Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: A prospective study of young women. Cancer Epidemiology Biomarkers and Prevention 2010; 19(10):2496–2502.

    [PubMed Abstract]
  • Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Exogenous hormone use: Oral contraceptives, postmenopausal hormone therapy, and health outcomes in the Nurses' Health Study. American Journal of Public Health 2016; 106(9):1631–1637.

    [PubMed Abstract]
  • Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Research 2014; 74(15):4078–4089.

    [PubMed Abstract]
  • Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine 2017; 377(23):2228–2239.

    [PubMed Abstract]
  • Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: A systematic review. Lancet 2003; 361(9364):1159–1167.

    [PubMed Abstract]
  • International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370(9599):1609–1621.

    [PubMed Abstract]
  • Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: Results from the EPIC Cohort. PLoS One 2016; 11(1):e0147029.

    [PubMed Abstract]
  • Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners' Oral Contraception Study. American Journal of Obstetrics and Gynecology 2017; 216(6):580.e1–580.e9.

    [PubMed Abstract]
  • Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncology 2018; 4(4):516–521.

    [PubMed Abstract]
  • Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiology, Biomarkers and Prevention 2013; 22(11):1931–1943.

    [PubMed Abstract]
  • Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: An individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncology 2015; 16(9):1061–1070.

    [PubMed Abstract]
  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Combined estrogen-progestogen contraceptives. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2012; 100A:283–311.

  • Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstetrics and Gynecology 2013; 122(1):139–147.

    [PubMed Abstract]
  • Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology 2016; 34(24):2888–2898.

    [PubMed Abstract]
  • Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. European Journal of Cancer 2010; 46(12):2275–2284.

    [PubMed Abstract]
  • Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. Journal of Clinical Oncology 2013; 31(33):4188–4198.

    [PubMed Abstract]
  • Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: Systematic review and meta-analysis. Journal of the National Cancer Institute 2014; 106(6):dju091.

    [PubMed Abstract]
  • Luan NN, Wu L, Gong TT, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: A meta-analysis of epidemiological studies. Cancer Causes and Control 2015; 26(1):65–78.

    [PubMed Abstract]
  • Murphy N, Xu L, Zervoudakis A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study. British Journal of Cancer 2017; 116(1):117–125.

    [PubMed Abstract]
  • Oral Contraceptives (Birth Control Pills) and Cancer Risk (2024)
    Top Articles
    Latest Posts
    Recommended Articles
    Article information

    Author: Jamar Nader

    Last Updated:

    Views: 5972

    Rating: 4.4 / 5 (75 voted)

    Reviews: 90% of readers found this page helpful

    Author information

    Name: Jamar Nader

    Birthday: 1995-02-28

    Address: Apt. 536 6162 Reichel Greens, Port Zackaryside, CT 22682-9804

    Phone: +9958384818317

    Job: IT Representative

    Hobby: Scrapbooking, Hiking, Hunting, Kite flying, Blacksmithing, Video gaming, Foraging

    Introduction: My name is Jamar Nader, I am a fine, shiny, colorful, bright, nice, perfect, curious person who loves writing and wants to share my knowledge and understanding with you.